Envair Technology has announced a 92% increase in revenue for the year ending December 2020. Impressively, the figures only include a partial impact of sales achieved since the acquisition of Total Containment Solutions (TCS) in August 2020, demonstrating the success of our organic growth strategy.
Envair Technology was formed in 2019 following the acquisition of Envair by ONFAB, both highly regarded leaders in containment. With the benefits of shared expertise now firmly embedded across the business, Envair Technology clients have the choice of an expanded product portfolio and full turnkey solutions. Headcount has risen to 120, with a series of senior appointments in engineering and QHSE.
The market for high specification containment is growing rapidly in Europe as drug development and API manufacturers seek to build increased flexibility and supply chain sustainability into their process manufacturing lines. Clients are continuing to respond positively to Envair Technology’s next generation products which protect workers and product in pharmaceutical manufacturing, R&D and pharmacy environments.
Focus on enabling drug discovery
We have invested in new product innovation in our isolator ranges, including integrations with the BD Cato™ medication workflow solution and SmartCompounders Chemo, plus the launch of a new range of aseptic manufacturing isolators. Engineering focus is on supporting the production of personalised medicines, improving patient safety and enabling drug discovery.
Further success has come from overseas expansion, particularly in Europe and the USA, with international sales now accounting for c.30% of revenue. The recent rebrand and launch of a consolidated group website is expected to further our global ambitions.
2021 looks set to be another remarkable year for growth, with customer orders since January at record levels.
Commenting on the news, Ian Plumb, Strategy Director, said: “These numbers are testament to the growth strategy, historic acquisition and how a strong management team, with a complementary product portfolio, can add significant value to customers. Our staff are motivated by working for a business that contributes a social good, helping the development of better treatments for diseases. This success is down to their dedication.”